AR048031A1 - Metodos para estimar la necesidad y efectividad de la terapia con antioxidantes - Google Patents

Metodos para estimar la necesidad y efectividad de la terapia con antioxidantes

Info

Publication number
AR048031A1
AR048031A1 ARP050100922A ARP050100922A AR048031A1 AR 048031 A1 AR048031 A1 AR 048031A1 AR P050100922 A ARP050100922 A AR P050100922A AR P050100922 A ARP050100922 A AR P050100922A AR 048031 A1 AR048031 A1 AR 048031A1
Authority
AR
Argentina
Prior art keywords
effectiveness
treatment
need
antioxidant
sample
Prior art date
Application number
ARP050100922A
Other languages
English (en)
Original Assignee
Crum Albert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crum Albert filed Critical Crum Albert
Publication of AR048031A1 publication Critical patent/AR048031A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7004—Stress
    • G01N2800/7009—Oxidative stress

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos de diagnosticos para evaluar la necesidad de que tiene un sujeto de un tratamiento con un antioxidante o, alternativamente, para determinar la eficacia de la utilizacion y la efectividad final de la terapia antioxidante en los sujetos que se encuentran bajo el tratamiento con antioxidantes. De manera más específica, los métodos de la presente son particularmente utiles en la evaluacion profiláctica de los individuos que se encuentran en riesgo de desarrollar enfermedades o afecciones en las que el estrés oxidante desempena una funcion importante, de manera que se puede recetar un régimen terapéutico adecuado para ese sujeto, conduciendo, de ese modo, a terapias alternativas y/o cambios en el estilo de vida. Métodos para evaluar la necesidad, la eficacia de la utilizacion y la efectividad de la terapia en los sujetos que recibieron la terapia con antioxidantes específicos y formulaciones inmunologicamente aumentadoras. Asimismo, se proporcionan juegos para medir el nivel de los marcadores del estrés oxidante y la cantidad de células inmunes. Kit, método de tratamiento. Reivindicacion 1: Método para evaluar la necesidad de tratamiento de un sujeto con un antioxidante que consiste en lo siguiente: a) recoger una muestra de fluido corporal de un sujeto de que se sospecha que necesita dicho tratamiento; b) medir la cantidad de peroxido lípido y los niveles de ácido piroglutámico en dicha muestra; c) medir el nivel de glutation en el plasma sanguíneo; d) comparar la cantidad del peroxido lípido y ácido piroglutámico en dicha muestra con aquella de un estándar normal; y e) comparar el nivel de glutation del plasma sanguíneo con aquel de un estándar normal; y en donde la presencia de peroxido lípido y ácido piroglutámico en dicha muestra y los niveles de glutation en el plasma sanguíneo presentes en cantidades que no encuadran en el rango normal, indican la necesidad de un tratamiento con antioxidantes.
ARP050100922A 2004-03-10 2005-03-10 Metodos para estimar la necesidad y efectividad de la terapia con antioxidantes AR048031A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/797,813 US20050202521A1 (en) 2004-03-10 2004-03-10 Methods of assessing the need for and the effectiveness of therapy with antioxidants

Publications (1)

Publication Number Publication Date
AR048031A1 true AR048031A1 (es) 2006-03-22

Family

ID=34920134

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100922A AR048031A1 (es) 2004-03-10 2005-03-10 Metodos para estimar la necesidad y efectividad de la terapia con antioxidantes

Country Status (3)

Country Link
US (5) US20050202521A1 (es)
AR (1) AR048031A1 (es)
WO (1) WO2005086827A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170102377A (ko) 2004-01-22 2017-09-08 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
FR2894030B1 (fr) * 2005-11-30 2008-07-04 Michel Brack Procede de determination d'un score representatif du stress oxydatif d'un patient, sur une echelle de 0 a 10
ES2525345T3 (es) * 2006-03-24 2014-12-22 Metanomics Gmbh Procedimiento de diagnóstico de diabetes de tipo II
US20070292403A1 (en) * 2006-05-11 2007-12-20 Avicena Group, Inc. Methods of treating a neurological disorder with creatine monohydrate
US7550299B2 (en) * 2006-08-03 2009-06-23 The United States Of America As Represented By The Department Of Veterans Affairs Method for predicting onset/risk of atrial fibrillation (AF)
AP2703A (en) * 2006-09-28 2013-07-24 Macfarlane Burnet Inst For Medical Res & Public Health Ltd A method of diagnosis and kit therefor
WO2008116108A2 (en) * 2007-03-20 2008-09-25 Pulse Health Llc Non-invasive human-health-measurement system and method
EP2185926B1 (en) 2007-08-03 2015-10-07 Virginia Commonwealth University Method for diagnosing acute cardiac ischemia
WO2009126764A1 (en) 2008-04-11 2009-10-15 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
KR100995334B1 (ko) * 2008-04-17 2010-11-19 한국원자력연구원 동물 모델을 이용한 항산화 기능성 평가 방법
WO2010012616A1 (en) * 2008-07-30 2010-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Blood glutathione as a biomarker for screening asymptomatic patients at risk for heart failure
WO2010132502A2 (en) 2009-05-11 2010-11-18 Cytotech Labs, Llc Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
US10933032B2 (en) 2013-04-08 2021-03-02 Berg Llc Methods for the treatment of cancer using coenzyme Q10 combination therapies
EP3730131A1 (en) 2013-09-04 2020-10-28 Berg LLC Methods of treatment of cancer by continuous infusion of coenzyme q10
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
WO2017160678A1 (en) * 2016-03-14 2017-09-21 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
KR20190131538A (ko) * 2017-03-31 2019-11-26 가부시키가이샤 히로츠 바이오 사이언스 암 환자의 치료 효과의 예측 및/또는 재발 모니터링

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0071485B1 (en) * 1981-07-30 1989-09-20 Akira Kimura Novel microorganisms derived from microorganisms of the genus escherichia by mutation and their use in the preparation of glutathione
US4859613A (en) * 1986-11-12 1989-08-22 Lawrence David A Immunoassays for glutathione and antibodies useful therein
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
US5635156A (en) * 1993-09-13 1997-06-03 University Of Pittsburgh Non-lethal methods for conditioning a recipient for bone marrow transplantation
TW517089B (en) * 1996-09-03 2003-01-11 Res Dev Foundation Assessment of intracellular cysteine and glutathione concentrations
US5891622A (en) * 1996-09-30 1999-04-06 Oxford Biomedical Research, Inc. Assessment of oxidative stress in vivo
ATE448782T1 (de) * 1996-12-31 2009-12-15 Antioxidant Pharmaceuticals Co Pharmazeutische glutathionpräparate und methoden zu dern verabreichung
US6569683B1 (en) * 1998-05-29 2003-05-27 Nikken Foods Co., Ltd. Use of oxidative stress diagnostic plot as a health indicator for assessing oxidative stress and its control in humans
WO1999064022A1 (en) 1998-06-10 1999-12-16 Crum Albert B Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system
US6667063B2 (en) * 1998-06-10 2003-12-23 Albert Crum Nutritional or therapeutic supplement and method
US6284219B1 (en) * 1998-06-30 2001-09-04 Phenome Sciences Inc. In vivo determination of metabolic function for use in therapy management
WO2001010231A2 (en) 1999-08-11 2001-02-15 The Proimmune Company L.L.C. Nutritious compositions and food components
US6527915B2 (en) * 2000-03-23 2003-03-04 Hercules Incorporated Proteins for use as pitch and stickies control agents in pulp and papermaking processes
AUPQ780300A0 (en) * 2000-05-23 2000-06-22 Gillam, Ian Dr Dosage formula/guidelines for a sports antioxidant
US6933120B2 (en) * 2000-06-20 2005-08-23 Michael D. Seidman Method of determining biological/molecular age
US20020034760A1 (en) * 2000-08-22 2002-03-21 George Kindness Combination and method presenting and utilizing DNA analysis and for diagnosis and treatment
US20020176900A1 (en) * 2000-11-22 2002-11-28 Inna Yegorova Compositions and methods for promoting a healthy cardiovascular system and enhancing blood flow

Also Published As

Publication number Publication date
US20200141956A1 (en) 2020-05-07
US9229014B2 (en) 2016-01-05
US20210041467A1 (en) 2021-02-11
US20080213905A1 (en) 2008-09-04
US20160341748A1 (en) 2016-11-24
US20050202521A1 (en) 2005-09-15
WO2005086827A3 (en) 2006-05-04
WO2005086827A2 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
AR048031A1 (es) Metodos para estimar la necesidad y efectividad de la terapia con antioxidantes
Venturelli et al. In vivo and in vitro evidence that intrinsic upper‐and lower‐limb skeletal muscle function is unaffected by ageing and disuse in oldest‐old humans
Hodak et al. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement
Fiuza-Luces et al. Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients
Tan et al. Rosacea: current state of epidemiology
Athayde et al. Development of normal reference values for seminal reactive oxygen species and their correlation with leukocytes and semen parameters in a fertile population
Kestenbaum et al. Impaired skeletal muscle mitochondrial bioenergetics and physical performance in chronic kidney disease
Mahfouz et al. Evaluation of chemiluminescence and flow cytometry as tools in assessing production of hydrogen peroxide and superoxide anion in human spermatozoa
Parsi et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis
Moster et al. The King–Devick (K–D) test of rapid eye movements: a bedside correlate of disability and quality of life in MS
Oliveira et al. Depression in dialysis patients and its association with nutritional markers and quality of life
WO2006073682A3 (en) Diagnostic test
AU2018239989A8 (en) Methods of measuring signaling pathway activity for selection of therapeutic agents
Deepinder et al. Should seminal oxidative stress measurement be offered routinely to men presenting for infertility evaluation?
Moors et al. Is the FAMACHA© chart suitable for every breed? Correlations between FAMACHA© scores and different traits of mucosa colour in naturally parasite infected sheep breeds
Painsipp et al. Experimental gastritis in mice enhances anxiety in a gender-related manner
Krause et al. Why do we determine α‐glucosidase activity in human semen during infertility work‐up?
Barrios‐Silva et al. Activin subfamily peptides predict chronological age in humans
BRPI0407213A (pt) Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados
Flaxel et al. Relationship between foveal threshold and visual acuity using the Humphrey visual field analyzer
Handayani et al. Anthropometric prediction equations for estimating muscle mass of elderly women
Yim et al. Comparative study of skin autofluorescence expression in atopic dermatitis and psoriasis: a prospective in vivo study
Zaki et al. Serum homocysteine and vitiligo
Arutyunov et al. Differences between passport and biological (actual) age in the population of Russian patients suffering from arterial hypertension (analysis of the «Hyperion» register)
Lee et al. Association between circulating adiponectin levels and osteoarthritis: A meta-analysis

Legal Events

Date Code Title Description
FB Suspension of granting procedure